# Phase 2 Carcinoma, Squamous Cell trials: 32 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 2 for Carcinoma, Squamous Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Carcinoma, Squamous Cell trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/carcinoma-squamous-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931664 | Evaluating Photodynamic Therapy Used to Treat Cutaneous Squamous Cell Carcinoma in Situ (isSCC) on the Face, Upper Extremities & Trunk. | The Center for Clinical and Cosmetic Research | Phase 2 | Recruiting | Cutaneous Squamous Cell Carcinoma in Situ, Facial Cutaneous Squamous Cell Carcinoma in Situ, Cutaneous Squamous Cell... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931664) |
| October 27, 2026 | NCT07896811 | Triplet Immunotherapy For Exhausted Cell Targets in Advanced Squamous Cell Carcinoma | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896811) |
| August 10, 2026 | NCT07755449 | CLEAR (Cervical Lymphatic Exclusion in Adjuvant Radiation) | Institut Català d'Oncologia | Phase 2 | Recruiting | Locally Advanced Head and Neck Squamous Cell Carcinoma | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755449) |
| June 29, 2026 | NCT07672782 | Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | GOG Foundation | Phase 2 | Not yet recruiting | Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer, Squamous Cell Carcinoma Vulva | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07672782) |
| June 5, 2026 | NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell... | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630168) |
| April 7, 2026 | NCT07513389 | Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) | Medical University of South Carolina | Phase 2 | Recruiting | Squamous Cell Carcinoma, Human Papilloma Virus (HPV), Oropharyngeal Squamous Cell Carcinoma (OPSCC) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07513389) |
| February 27, 2026 | NCT07435376 | Intra-lesional Tumor Boost for Bulky Cervical Cancer | Seoul National University Bundang Hospital | Phase 2 | Recruiting | Cervical Cancer, Squamous Cell Carcinoma of Cervix | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07435376) |
| February 19, 2026 | NCT07419464 | 5-Fluorouracil Response and Optimization STudy (The FROST Trial) | Washington University School of Medicine | Phase 2 | Recruiting | Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07419464) |
| January 22, 2026 | NCT07361133 | Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer | National Cancer Institute, Egypt | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma, Advanced Head and Neck Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07361133) |
| January 16, 2026 | NCT07346196 | A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck | University of Chicago | Phase 2 | Not yet recruiting | Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07346196) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| October 31, 2025 | NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Colo-rectal Cancer (dMMR/MSI-H CRC), Hepatocellular... | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223424) |
| October 9, 2025 | NCT07214987 | PDT For Induction Therapy For Head And Neck Cancer | Massachusetts General Hospital | Phase 2 | Recruiting | Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma, Head and Neck Cancer | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07214987) |
| October 6, 2025 | NCT07209189 | Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch... | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Recruiting | Head and Neck Cancer, Squamous Cell Carcinoma, Oral Cavity Cancer, Oropharyngeal Cancer, Laryngeal Cancer, Sinonasal... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209189) |
| April 23, 2025 | NCT06940180 | Toripalimab With Chemotherapy for Sinus Cancer | Dana-Farber Cancer Institute | Phase 2 | Recruiting | Sinonasal Cancer, Paranasal Sinus Neoplasms, Squamous Cell Carcinoma, Sinonasal Undifferentiated Carcinoma, Locally... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06940180) |
| March 11, 2025 | NCT06869473 | Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic... | Gruppo Oncologico del Nord-Ovest | Phase 2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06869473) |
| February 17, 2025 | NCT06831149 | Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction | Sponsor not shown (see the record) | Phase 2 | Recruiting | Squamous Cell Carcinoma, Pharyngocutaneous Fistula | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06831149) |
| February 7, 2025 | NCT06814158 | Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Esophageal Squamour Cell Cancer | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06814158) |
| December 13, 2024 | NCT06731933 | Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin | Stanford University | Phase 2 | Recruiting | Squamous Cell Carcinoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06731933) |
| November 1, 2024 | NCT06669572 | Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment | University of Chicago | Phase 2 | Recruiting | Carcinoma, Squamous Cell, Anorectal Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06669572) |
| August 29, 2024 | NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 | Not yet recruiting | Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06578871) |
| April 25, 2024 | NCT06383728 | Neoadjuvant Targeted Therapy in Patients With Resectable EGFR-mutated Lung Squamous Cell Carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 | Recruiting | Lung Cancer, Carcinoma, Squamous Cell | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06383728) |
| November 18, 2023 | NCT06137274 | Phase 2 Trial of Adaptive Radiotherapy Boost for HNSCC | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | Recruiting | Squamous Cell Carcinoma, Head and Neck Cancer | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06137274) |
| July 27, 2023 | NCT05964101 | Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Phase 2 | Recruiting | Neoplasms, Carcinoma, Squamous, Antineoplastic Agents | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05964101) |
| May 24, 2022 | NCT05388773 | Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | Sponsor not shown (see the record) | Phase 2 | Recruiting | Oropharynx Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05388773) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| The First Affiliated Hospital of Guangzhou Medical University | 2 |
| University of Chicago | 2 |
| Seoul National University Bundang Hospital | 1 |
| Medical College of Wisconsin | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Mayo Clinic | 1 |
| National Cancer Institute (NCI) | 1 |
| GOG Foundation | 1 |
| Washington University School of Medicine | 1 |
| Gruppo Oncologico del Nord-Ovest | 1 |
| National Institute on Deafness and Other Communication Disorders (NIDCD) | 1 |
| National Cancer Institute, Egypt | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| Shanghai Jiao Tong University School of Medicine | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| The Center for Clinical and Cosmetic Research | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Stanford University | 1 |
| Jiangxi Provincial Cancer Hospital | 1 |
| M.D. Anderson Cancer Center | 1 |
| Institut Català d'Oncologia | 1 |
| Medical University of South Carolina | 1 |
| Massachusetts General Hospital | 1 |
| Charite University, Berlin, Germany | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 21 |
| China | 5 |
| Italy | 2 |
| South Korea | 1 |
| Egypt | 1 |
| Australia | 1 |
| Canada | 1 |
| Spain | 1 |
| Germany | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
- [Outpatient care facilities in the United States](https://specstream.ai/data/businesses/outpatient-care-facilities/united-states)
- [Sports medicine clinics in the United States](https://specstream.ai/data/businesses/sports-medicine-clinics/united-states)
- [Assisted living facilities in the United States](https://specstream.ai/data/businesses/assisted-living-facilities/united-states)
- [Contractors in the United States](https://specstream.ai/data/businesses/contractors/united-states)
